ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 22.6 TWD 1.12%
Market Cap: 17.9B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one ScinoPharm Taiwan Ltd stock under the Base Case scenario is 20.79 TWD. Compared to the current market price of 22.6 TWD, ScinoPharm Taiwan Ltd is Overvalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
20.79 TWD
Overvaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.1
P/S
P/S
Price to Sales
5.1
vs History
98
vs Industry
22
Median 3Y
6.5
Median 5Y
6.6
Industry
2.5
Forward
5.8
More Details
44.7
P/E
P/E
Price to Earnings
44.7
vs History
98
vs Industry
7
Median 3Y
69.6
Median 5Y
72.7
Industry
21.8
Forward
84.3
More Details
29.6
P/OCF
P/OCF
Price to OCF
29.6
vs History
47
vs Industry
8
Median 3Y
33.9
Median 5Y
29.3
Industry
16.1
More Details
72.1
P/FCFE
P/FCFE
Price to FCFE
72.1
vs History
31
vs Industry
1
Median 3Y
74.7
Median 5Y
42
Industry
23.8
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
85
vs Industry
39
Median 3Y
1.9
Median 5Y
2
Industry
2.1
More Details
4
EV/S
EV/S
Enterprise Value to Sales
4
vs History
98
vs Industry
24
Median 3Y
5.3
Median 5Y
5.4
Industry
2.7
Forward
4.6
More Details
10.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.2
vs History
98
vs Industry
14
Median 3Y
13.4
Median 5Y
13.6
Industry
5.2
More Details
15.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.4
vs History
98
vs Industry
19
Median 3Y
21.6
Median 5Y
22.1
Industry
13.5
Forward
583.3
More Details
31.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
31.6
vs History
98
vs Industry
9
Median 3Y
50.9
Median 5Y
50.2
Industry
16.8
Forward
66.8
More Details
23.3
EV/OCF
EV/OCF
Enterprise Value to OCF
23.3
vs History
49
vs Industry
10
Median 3Y
27.5
Median 5Y
24.7
Industry
15.2
More Details
41.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
41.5
vs History
28
vs Industry
3
Median 3Y
42.9
Median 5Y
32.3
Industry
19.3
More Details
1.8
EV/IC
EV/IC
Enterprise Value to IC
1.8
vs History
90
vs Industry
34
Median 3Y
2.2
Median 5Y
2.2
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
ScinoPharm Taiwan Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
TW
ScinoPharm Taiwan Ltd
TWSE:1789
17.7B TWD 5.1 44.7 15.4 31.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 18.5 90.3 48.5 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.6 169.4 253.9
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average P/S: 382 942.4
5.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average P/E: 33.8
44.7
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average EV/EBITDA: 415.2
15.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average EV/EBIT: 1 813.3
31.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.9
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 211,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.